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 Abstract  
Introduction 
It is challenging to identify health state utilities associated with psoriasis because generic preference-
based measures may not capture the impact of dermatological symptoms.  The Psoriasis Area Severity 
Index (PASI) is one of the most commonly used psoriasis rating scales in clinical trials.  The purpose of 
this study was to develop a utility scoring algorithm for the PASI.  
Methods  
Forty health states were developed based on PASI scores of 40 clinical trial patients.  Health states were 
valued in time trade-off interviews with UK general population participants.  Regression models were 
conducted to crosswalk from PASI scores to utilities (e.g., OLS linear, random effects, mean, robust, 
spline, quadratic). 
Results 
A total of 245 participants completed utility interviews (51.4% female; mean age = 45.3y).  Models 
predicting utility based on the four PASI location scores (head, upper limbs, trunk, lower limbs) had 
better fit/accuracy (e.g., R
2
, mean absolute error [MAE]) than models using the PASI total score.  
Head/upper limb scores were more strongly associated with utility than trunk/lower limb.  The 
recommended model is the OLS linear model based on the four PASI location scores (R
2
 = 0.13; MAE = 
0.03).  An alternative is recommended for situations when it is necessary to estimate utility based on the 
PASI total score. 
Conclusions 
The recommended scoring algorithm may be used to estimate utilities based on PASI scores of any 
treatment group with psoriasis.  Because the PASI is commonly used in psoriasis clinical trials, this 
scoring algorithm greatly expands options for quantifying treatment outcomes in cost-effectiveness 
analyses of psoriasis therapies.  Results indicate that psoriasis of the head/upper limbs could be more 
important than trunk/lower limbs, suggesting reconsideration of the standard PASI scoring approach. 
Keywords: Health state utilities; Psoriasis Area Severity Index (PASI); psoriasis  
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 Introduction 
Decisions regarding allocation of healthcare resources are often informed by cost-effectiveness 
analyses in which treatments are assessed in terms of cost per quality-adjusted life year (QALY) gained 
[1].  QALYs are calculated using health state utilities, which are scores representing the strength of 
preference for a given health state [2, 3].  Although utilities for specific patient populations and 
treatment groups are often derived from generic preference-based measures such as the EQ-5D, these 
generic measures are not relevant or sensitive to every medical condition.  Therefore, there is growing 
interest in development of preference-based scoring algorithms for condition-specific measures to 
estimate utilities in situations when generic instruments are not appropriate [4]. 
Dermatoses such as psoriasis may present a serious challenge for generic preference-based 
measures.  For example, although the EQ-5D has demonstrated adequate measurement properties in 
some studies with psoriasis patients [5], this measure may be insensitive to psoriasis severity or 
treatment-related change [6-8].  The five items of the EQ-5D assess level of mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression.  These concepts appear to have limited overlap with 
the impact of psoriasis [9].  To address this limitation of the EQ-5D, researchers have explored the 
possibility of adding a sixth item focusing specifically on psoriasis [7, 8].  In addition, there is a utility 
scoring algorithm associated with the Dermatology Life Quality Index (DLQI), a measure of dermatology-
related quality of life impact [10, 11].  However, the DLQI is not psoriasis-specific, and it is not one of the 
most broadly used outcome instruments in psoriasis trials.  Therefore, it has limited usefulness for 
deriving utilities specific to psoriasis.   
One of the most commonly used psoriasis measures in clinical trials is the clinician-rated 
Psoriasis Area Severity Index (PASI) [12-16].  If utilities could be derived from PASI scores, it would be 
possible to obtain utilities from the wide range of clinical trials in which the PASI was administered.  This 
would greatly expand the available options for estimating utilities that could be used in cost-
effectiveness analyses of psoriasis treatments.  Therefore, the purpose of this study was to develop an 
algorithm for deriving utilities from PASI scores.   
Methods 
Overview of study design 
This study design followed three steps similar to other studies that have derived preference-
based scoring algorithms for condition-specific measures [17-20].  First, health states corresponding to a 
range of PASI scores were developed.  Second, utilities for each health state were obtained in a time 
trade-off (TTO) valuation study with general population respondents.  Third, regression modeling was 
performed to identify a scoring algorithm for estimating utility based on any PASI score. 
PASI  
The PASI is a clinician-rated measure of psoriasis severity in four locations: head, upper limbs, 
trunk, and lower limbs [13].  For each location, a score is calculated based on psoriasis severity and 
surface area involvement.  The severity score is comprised of three attributes (erythema [redness], 
induration [thickness], desquamation [scaling]) rated on a scale from 0 (none) to 4 (very severe) and 
summed for a severity score ranging from 0 to 12.  The surface area score ranges from 0 (0%) to 6 (90  ? 
100%).  Each of the four body location scores is calculated as the severity sum score multiplied by the 
surface area score (possible range = 0 to 72).  Each location score is then multiplied by a specific 
correction score (head = 0.1, upper limbs = 0.2, trunk = 0.3, lower limbs = 0.4), with the adjusted scores 
summed to produce a total score ranging from 0 to 72.   
Health state development 
Studies developing preference-based scoring algorithms for condition-specific measures 
typically derive health states using psychometric techniques like Rasch analysis [4].  However, this 
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 analytic approach was not appropriate for the PASI because it is not a conventional multi-item 
questionnaire.  Instead, health states were developed for the subsequent utility valuation study based 
on PASI data from a clinical trial dataset [21].  The trial data for each patient included the PASI total 
score as well as the redness, thickness, scaling, and surface area scores for each of the four locations.  
Then, 40 health states were developed to correspond to the PASI scores of patients from this trial 
dataset.  The 40 patients were selected to represent a wide range of PASI scores (listed in Table 1), while 
emphasizing the range most commonly observed in a clinical trial (i.e., roughly PASI 10 to 25).  An effort 
was made to identify some health states with consistent severity across the four locations (e.g., health 
state 26) and other health states with unbalanced scores (e.g., health state 17, which has a head score 
that is more severe than the scores of the other three locations).  This approach ensured that the 40 
health states represented a wide range of psoriasis severity, and each health state corresponded to an 
actual PASI profile of a patient treated for psoriasis in a clinical trial. 
With the input of four dermatologists, health state language was drafted based on the PASI 
scoring system.  Each health state consisted of 16 statements describing the level of redness, thickness, 
scaling, and surface area coverage within the four locations (see Figure 1 for an example of a health 
state).  An  ? ?ǆ ? ? ?ƉĂŐĞǁŝƚŚƉŚŽƚŽƐ (provided by the dermatologists) representing each level of 
redness, thickness, and scaling was presented along with the health states ƚŽĞŶƐƵƌĞƚŚĂƚƌĞƐƉŽŶĚĞŶƚƐ ?
TTO decisions were based on a reasonably accurate understanding of psoriasis severity levels. 
Participants 
Participants in the pilot and valuation studies were required to be at least 18 years old, reside in 
the United Kingdom (UK), and able to understand the interview procedures.  Inclusion criteria did not 
specify clinical characteristics because interviews were intended to lead to a scoring algorithm for 
estimating utilities for cost-utility analyses in submissions to health technology assessment agencies, 
which often prefer that utilities represent general population values [22-24].  Participants were 
recruited via newspaper and online advertisements.   
Pilot study 
The health states were tested in a pilot study in December 2014 with 19 general population 
participants in London (29.4% female; mean [SD] age = 36.1 [12.7] years; age range = 19 to 67).  The 
time horizon used in the TTO method and the number of health states per participant were varied.  
Participants generally reported that the health states were clear and easy to understand.  Some 
participants suggested minor revisions in formatting, and the health states were edited accordingly.  All 
TTO methods yielded utility scores in a reasonable range with logical discrimination among health 
states.   
Valuation study 
The valuation study was conducted in Edinburgh and London in January and February, 2015.  
Participants were required to provide written informed consent before completing study procedures, 
and all procedures and materials were approved by an independent Institutional Review Board (Ethical 
& Independent Review Services; Study Number 14145-01). 
The 40 health states (listed in Table 1) were categorized into five severity groups ranging from 
mild (health states 1 to 8) to severe (health states 33 to 40).  Each participant rated five health states, 
including one selected randomly from each of the five severity groups.  As an introductory task, 
participants first ranked the health states in order of preference.  Then, utilities for each health state 
were obtained in a TTO task.  A 20-year TTO time horizon with 5% trading (1-year) increments was used 
because it was easy for participants to understand in the pilot study, and this relatively long time 
horizon is consistent with the chronic nature of psoriasis.  Following standard utility assessment 
methodology [1-3], participants were offered a choice between living 20 years in the health state being 
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 rated versus living shorter amounts of time in full health.  For each health state, choices were presented 
in an order that alternated between longer and shorter durations in full health (e.g., 20 years, 0, 19, 1, 
18 ?).  The utility score was calculated based on the choice in which the respondent was indifferent 
between y years/months in the health state being evaluated and x years/months in full health (followed 
by dead).   
The resulting utility estimate (u) is calculated as u = x / y.  Each health state rated as better than 
dead received a utility score on a scale with the anchors of dead (0) and full health (1).  When 
participants indicated that a health state was worse than dead, respondents were offered a choice 
between immediate death (alternative 1) and a 20-year life span (alternative 2) beginning with varying 
amounts of time in the health state being rated, followed by full health for the remainder of the time 
horizon.  For these health states, the current study used a bounded scoring approach (u = -x / t, where x 
is the time in full health, and t is the total life span of alternative 2), which is commonly used to avoid 
highly skewed distributions for negative utilities [25, 26].  
Regression analyses for modeling health state values 
Regression models estimated the relationship between PASI scores and TTO utilities, following 
an established approach [4, 18-20, 27].  First, eight models were run using the PASI total score as the 
independent variable, followed by a parallel set of models with the four PASI location scores as 
independent variables.   
The eight models began with the (1) ordinary least squares (OLS) linear regression model 
estimating the best-fitting linear relationship between PASI scores and utility: E(yi ?A?ɴ0 A?ɴ1(xi ?ǁŚĞƌĞɴ0 
is tŚĞŝŶƚĞƌĐĞƉƚ ?ɴ1 is the coefficient for PASI score xi, and yi is the utility.  Subsequent models included: 
(2) random effects mixed model (accounting for the fact that each respondent provided multiple 
utilities, which may not be independent of each other); (3) mean model (providing an aggregate level 
prediction model, equally weighted across the 40 heath states); (4) robust linear regression model 
(reducing the influence of outliers by down-weighting such data points in the estimation) [28]; (5) linear 
spline model (allowing for a bend Žƌ “ŬŶŽƚ ?in the data; essentially two connected linear models); (6) 
robust regression spline model; (7) OLS model with a quadratic term (allowing for a non-linear 
relationship between PASI and utility); and (8) robust model with a quadratic term.  Models were 
evaluated and compared based on indices of model fit (R
2
, adjusted R
2
), accuracy of estimation (mean 
absolute error [MAE], frequency of large absolute prediction errors), plots of the mean residuals for 
each model, and line graphs depicting the relationship between PASI and utility.   
Results 
Valuation survey: respondent characteristics 
A total of 285 potential participants (157 London; 128 Edinburgh) were scheduled for interviews, 
and 257 (139 London; 118 Edinburgh) attended and completed their interviews.  Nine of the 257 
participants (five London; four Edinburgh) were either unable to complete the utility interview 
procedures (seven who had difficulty understanding the TTO task and/or the health state content) or 
were found to be ineligible during the interview process (one with cognitive impairment and one with a 
psychiatric disorder that interfered with their ability to complete the study procedures).  Thus, a total of 
248 valid utility interviews were conducted (134 London; 114 Edinburgh).  Three participants who 
provided negative (i.e., worse than dead) utilities for all five health states were excluded from analyses.  
Therefore, the analysis sample includes 245 respondents (131 London; 114 Edinburgh).  The sample was 
51.4% female (n = 126), with a mean age of 45.3 years.  The most commonly reported ethnic/racial 
backgrounds were White (74.3%), Black (9.4%), and Asian (9.0%).  Self-reported marital status included 
single (51.0%), married/living with a partner (36.7%), divorced (8.6%), and widowed (2.4%).  Most 
participants reported being employed (35.1% full-time and 30.6% part-time).  A little under half of the 
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 sample had completed a university degree (33.9%) or a postgraduate degree (13.1%).  The most 
commonly reported health conditions were depression (19.2%), anxiety (14.7%), hypertension (9.0%), 
arthritis (8.2%), and diabetes (7.8%).   
TTO utility values 
Each health state received at least 29 valuations.  As expected, health states representing higher 
total PASI scores (i.e., greater psoriasis severity) tended to have lower mean utilities (Table 1).  Some 
health state utilities deviated from the expected order based on total PASI score, likely due to the 
influence of the PASI location (e.g., head vs. upper limb) on respondent preferences.  For example, the 
utility score for health state 17 (mean utility = 0.77; total PASI = 14.4; head = 32) was lower than the 
utility of health state 22 (mean utility = 0.80; total PASI = 18.4; head = 0). 
A series of t-tests compared mean utilities across subgroups, finding minimal differences.  There 
were no significant differences between men and women.  Of the 40 health states, there was a 
statistically significant age difference (median split: older vs. younger) for only one health state (health 
state 13; p = 0.01).  Comparisons between the London and Edinburgh subgroups found significant 
differences for only three of the 40 health states (health states 3, 17, and 27; p < 0.05). Comparisons 
between participants who worked full-time or part-time (n = 161) versus those who did not (n = 84) also 
found significant differences for only three of the 40 health states (health states 6, 16, and 26; p <0.05).  
Similarly, comparisons between participants who were married or living with a partner (n = 90) versus 
the other participants (n = 155) found significant differences for only four of the 40 health states (health 
states 10, 26, 27, and 39; p <0.05).  Comparisons between participants with a university degree or higher 
(n = 115) versus those who did not have a university degree (n = 130) found significant differences for 
four of the 40 health states (health states 3, 7, 23, and 34; p <0.05).  When differences were observed, 
they were not in a consistent direction (i.e., no group had consistently higher or lower scores than the 
comparison group).  Furthermore, with an adjustment for multiple comparisons (e.g., a Bonferroni 
correction), none of these differences would be considered statistically significant.  Overall, these 
comparisons suggest that demographic variables did not have a meaningful or consistent impact on 
utility scores.   
Regression modeling based on the PASI total score 
Generally, model fit and accuracy are similar across the regression models based on the PASI 
total score, although some differences emerged (Table 2, Figure 2).  There is minimal difference among 
the parameter estimates of the first three models (OLS linear model, the random effects model, and the 
mean model) among all truly comparable statistics.  Although R
2
 for the mean model (0.7847) is 
substantially higher, this cannot be compared to any other model because this model does not assess 
the same data points.   
The robust models, which minimize the influence of outliers and high leverage points, yield 
results that are notably different from their OLS model counterparts.  The robust models have higher 
intercepts and less steep slopes, resulting in higher utility scores, particularly in the more severe part of 
the PASI score range.  Fit/accuracy statistics are not directly comparable between robust and OLS 
models (e.g., R
2
 is not assessing the same data variance).   
The two types of nonlinear models (spline and quadratic) offer some improvement in model 
fit/accuracy over corresponding linear models.  Model differences are highlighted by the predicted plots 
(Figure 2).  The two nonlinear models are similar in terms of utility estimates, fit, and accuracy.  The 
spline model is preferred over the quadratic for two reasons.  The spline performed slightly better than 
the quadratic (e.g., R
2
, MAE, frequency of absolute errors), and perhaps more importantly, its linear 
trends are either descending or flat.  In contrast, the quadratic curves upward for PASI scores over 51.9 
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 for the OLS quadratic and 43.0 for the robust quadratic (Figure 2), which could lead to nonsensical utility 
estimates among patients with severe psoriasis.   
Regression modeling based on the four PASI location scores 
Results of models with the four PASI location scores followed the same general patterns as the 
models described above using the PASI total score.  However, running the models using the four PASI 
location scores resulted in small but consistent improvements in model fit/accuracy over the PASI total 
score, including increased R
2
 as well as reduced MAE and frequency of absolute errors.  Parameter 
estimates indicate that head and upper limb scores were more strongly associated with utility than 
trunk and lower limb (Table 3). 
For the spline and quadratic model, however, the same problem emerged as described above 
for the total score quadratic model.  These models yielded utilities that begin to increase, rather than 
continuing to decrease, in the far upper range of PASI scores that represent greatest psoriasis severity.  
This pattern, which results in illogical utility scores for the most severe health states, occurred with the 
trunk and lower limbs scores in the quadratic, as well as the trunk in the spline model (Figure 3).   
Discussion  
Given that the four body locations clearly differed in terms of impact on preference, it is 
recommended that a model with the four PASI location scores as independent variables be used to 
estimate utilities based on the PASI.  The models predicting utility based on the four PASI location scores 
generally had better fit/accuracy than models using the PASI total score.  Among the models using the 
four location scores, none offered notable improvement over the simple linear model.  Therefore, the 
OLS linear model based on the four PASI location scores is recommended as the primary algorithm for 
deriving utilities from PASI scores (see scoring algorithm in Table 4). 
In situations where the four PASI location scores are not available, it would be reasonable to use 
a scoring algorithm based on the PASI total score.  Among the models based on the total score, the 
spline model with a knot at 29 offers the best model fit and accuracy.  Therefore, this model is 
recommended for use when it is necessary to derive utilities from the PASI total score (see scoring 
algorithm in Table 4).   
It was concluded that the robust models would not be recommended for future use.  When 
evaluating these models, one must determine the extent to which outliers can be disregarded.  Utility 
valuation studies, including the current study, typically elicit a wide range of values for each health state, 
with substantial heterogeneity and outliers.  Because outliers such as negative scores and scores at the 
ceiling are a common and expected part of the utility valuation process, it is difficult to determine cut 
points at which these data points should be disregarded.  Therefore, the robust models that largely 
disregard these values were ultimately not considered optimal for this scoring algorithm.  Models that 
could lead to illogical relationships among utilities for individuals with severe psoriasis are also not 
recommended for future use (i.e., all quadratic models and the spline model using the four PASI location 
scores). 
When deciding whether to derive utilities with a condition-specific preference-based (CSPB) 
approach, such as the scoring algorithm provided in the current study, advantages and disadvantages 
should be considered.  CSPB measures are generally thought to be more sensitive to disease severity 
and treatment-related change than generic utility measures such as the EQ-5D [4].  However, CSPB 
measures sacrifice some comparability across diseases, studies, and cost-utility models, whereas utilities 
derived from generic measures have the advantage of maximizing comparability [4, 29].  Despite this 
limitation, there are situations when CSPB measures are the best available option for deriving utilities, 
such as when generic instruments do not assess content relevant to a particular disease.  Psoriasis may 
present such a situation because the commonly used generic instruments do not assess dermatological 
Ac
ce
ed
Ma
us
cri
pt
 symptoms or their impact.  Other recent research has addressed this challenge by adding psoriasis-
specific dimensions to the EQ-5D to improve sensitivity to skin clarity, particularly at the highest PASI 
levels [7].  Future research could examine the relationship between utilities based on the EQ-5D with 
added dimensions and utilities derived directly from the PASI using the algorithm derived in the current 
study. 
Findings from the models using the four PASI location scores could have important implications 
for scoring and interpretation of PASI results in clinical trials.  In the regression model results, the 
parameter estimates and statistical significance levels indicate that psoriasis of the head had the 
strongest impact on health state preference, followed by the upper limbs, while the trunk and lower 
limbs had a much weaker association with utility.  In addition to the statistical results, this difference 
among the four body locations is apparent from visual inspection of the lines/curves in Figure 3.  The 
importance of head/upper limb psoriasis was also apparent during the interviews.  Many respondents 
explained their preferences by reporting that skin patches of the head and upper limbs would be most 
troubling because these locations are most visible and least likely to be covered by clothes.   
In contrast to current results highlighting importance of the head and upper limbs, the standard 
PASI scoring algorithm is more heavily weighted toward psoriasis of the lower limbs and trunk.  
Therefore, the standard PASI scoring may not optimally represent the impact of psoriasis.  This finding 
should be interpreted with caution because the current preference values were derived from a general 
population sample.  It is not known whether patients would agree that psoriasis of the head and upper 
limbs is most important.  Therefore, it would be useful to replicate this preference task with a patient 
sample.  If results from patients were similarly weighted toward the head and upper limbs, this finding 
would suggest re-evaluating the standard scoring approach of the PASI so that scores would better 
represent the impact of psoriasis. 
A limitation of the proposed scoring algorithm is that utility is derived only from the four visible 
aspects of psoriasis assessed by the PASI ?ƌĂƚŚĞƌƚŚĂŶƚŚĞƉĂƚŝĞŶƚ ?ƐďƌŽĂĚĞƌĞǆƉĞƌŝĞŶĐĞŽĨƉƐŽƌŝĂƐŝƐ.  
Symptoms such as pain and itching are not represented.  While these symptoms likely co-occur with the 
visible signs captured by the PASI to some extent, it is possible that utilities derived from the PASI may 
ŶŽƚďĞĞŶƚŝƌĞůǇĐŽŶƐŝƐƚĞŶƚǁŝƚŚƚŚĞƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞŽĨƉƐŽƌŝĂƐŝƐ ?dŽĂĚĚƌĞƐƐƚŚŝƐƉŽƚĞŶƚŝĂůůŝŵŝƚĂƚŝŽŶ ?
future research could examine validity of the proposed utility scoring algorithm by comparing the 
resulting utility scores to scores in instruments ĚĞƐŝŐŶĞĚƚŽĂƐƐĞƐƐƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞŽĨƉƐŽƌŝĂƐŝƐ.  For 
example, with a dataset that includes both the PASI and DLQI, it would be possible to run correlations 
between PASI-based utilities and the DLQI scores, which represent the quality of life impact associated 
with dermatological conditions.  This analysis would provide an indication of the extent to which the 
ƉƌŽƉŽƐĞĚƵƚŝůŝƚǇƐĐŽƌŝŶŐĂůŐŽƌŝƚŚŵŝƐĐŽŶƐŝƐƚĞŶƚǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐŽǀĞƌĂůůĞǆƉĞƌŝĞŶĐĞŽĨ psoriasis and its 
impact. 
In sum, the current study provides a new method for obtaining utilities corresponding to a wide 
range of psoriasis severity.  With the scoring algorithm provided in this study, utilities can be derived 
from any treatment group or patient sample whose psoriasis was rated with the PASI.  Because the PASI 
is commonly used in clinical trials, the recommended scoring algorithm greatly expands options for 
quantifying outcomes in cost-effectiveness analyses, facilitating more accurate modeling to inform 
resource allocation decisions.   
 
 
  
Ac
ce
pte
d M
an
u
cri
pt
 References 
1. Brazier JR, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and Valuing Health benefits for 
Economic Evaluation. New York: Oxford University Press, 2007. 
2. Feeny D. Preference-based measures: utility and quality-adjusted life years. In: Fayers P, Hays R, 
eds. Assessing quality of life in clinical trials 2nd ed. New York: Oxford University Press, 
2005:405-31. 
3. Torrance GW. Measurement of health state utilities for economic appraisal. Journal of health 
economics 1986;5(1):1-30  
4. Brazier JE, Rowen D, Mavranezouli I, et al. Developing and testing methods for deriving 
preference-based measures of health from condition-specific measures (and other patient-
based measures of outcome). Health technology assessment 2012;16(32):1-114 doi: 
10.3310/hta16320[published Online First: Epub Date]|. 
5. Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and 
responsiveness. Eur J Health Econ 2014 doi: 10.1007/s10198-014-0638-9[published Online First: 
Epub Date]|. 
6. Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of 
dermatological conditions and therapies. Dermatology 2012;225(1):45-53 doi: 
10.1159/000339865[published Online First: Epub Date]|. 
7. Pickard AS, Gooderham M, Hartz S, Nicolay C. EQ-5D health utilities: exploring ways to improve 
upon responsiveness in psoriasis. J Med Econ 2017;20(1):19-27 doi: 
10.1080/13696998.2016.1219359[published Online First: Epub Date]|. 
8. Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-
specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from 
a feasibility study in the UK. Value Health 2013;16(8):1156-62 doi: 
10.1016/j.jval.2013.10.003[published Online First: Epub Date]|. 
9. Lebwohl M. Psoriasis. Lancet 2003;361(9364):1197-204 doi: 10.1016/S0140-6736(03)12954-
6[published Online First: Epub Date]|. 
10. Blome C, Beikert FC, Rustenbach SJ, Augustin M. Mapping DLQI on EQ-5D in psoriasis: 
transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res 
2013;305(3):197-204 doi: 10.1007/s00403-012-1309-2[published Online First: Epub Date]|. 
11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for 
routine clinical use. Clin Exp Dermatol 1994;19(3):210-6  
12. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 
Suppl 2:ii65-8; discussion ii69-73 doi: 10.1136/ard.2004.031237[published Online First: Epub 
Date]|. 
13. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 
1978;157(4):238-44  
Ac
ce
t d
M
nu
scr
ipt
 14. Gaspari AA, Tyring SK. Commonly Applied Clinical Trial Endpoints for Psoriasis and PsA. Clinical 
and Basic Immunodermatology. London, UK: Springer, 2008:526. 
15. Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of 
PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-
severe psoriasis. J Drugs Dermatol 2014;13(5):554-62  
16. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and 
outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest 
Dermatol 2010;130(4):933-43 doi: 10.1038/jid.2009.391[published Online First: Epub Date]|. 
17. Mavranezouli I, Brazier JE, Rowen D, Barkham M. Estimating a preference-based index from the 
Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D. 
Med Decis Making 2013;33(3):381-95 doi: 10.1177/0272989X12464431[published Online First: 
Epub Date]|. 
18. Rentz AM, Kowalski JW, Walt JG, et al. Development of a preference-based index from the 
National Eye Institute Visual Function Questionnaire-25. JAMA Ophthalmol 2014;132(3):310-8 
doi: 10.1001/jamaophthalmol.2013.7639[published Online First: Epub Date]|. 
19. Yang Y, Brazier J, Tsuchiya A, Coyne K. Estimating a preference-based single index from the 
Overactive Bladder Questionnaire. Value Health 2009;12(1):159-66 doi: 10.1111/j.1524-
4733.2008.00413.x[published Online First: Epub Date]|. 
20. Yang Y, Brazier JE, Tsuchiya A, Young TA. Estimating a preference-based index for a 5-
dimensional health state classification for asthma derived from the asthma quality of life 
questionnaire. Med Decis Making 2011;31(2):281-91 doi: 
10.1177/0272989X10379646[published Online First: Epub Date]|. 
21. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for 
psoriasis. N Engl J Med 2012;366(13):1181-9 doi: 10.1056/NEJMoa1109017[published Online 
First: Epub Date]|. 
22. CADTH (Canadian Agency for Drugs and Technologies in Health). Guidelines for the economic 
evaluation of health technologies: Canada [3rd] ed. Ottawa: Canadian Agency for Drugs and 
Technologies in Health, 2006. 
23. NICE (National Institute for Health and Care Excellence). Process and methods guides: Guide to 
the methods of technology appraisal 2013. In: NICE (National Institute for Health and Clinical 
Excellence), ed. London, UK: NICE, 2013. 
24. PBAC (Pharmaceutical Benefits Advisory Committee). Guidelines for preparing submissions to 
PBAC, Version 4.4. Canberra, Australia: Australian Government Department of Health, PBAC, 
June 2013:344. 
25. Matza LS, Sapra SJ, Dillon JF, et al. Health state utilities associated with attributes of treatments 
for hepatitis C. Eur J Health Econ 2015;16(9):1005-18 doi: 10.1007/s10198-014-0649-
6[published Online First: Epub Date]|. 
26. Rowen D, Brazier J. Health Utility Measurement. In: Glied S, Smith P, eds. The Oxford Handbook 
of Health Economics. New York: Oxford University Press, 2011:788-813. 
Ac
pte
d M
an
u
cri
pt
 27. Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. Estimation of a 
preference-based index from a condition-specific measure: the King's Health Questionnaire. 
Med Decis Making 2008;28(1):113-26 doi: 10.1177/0272989X07301820[published Online First: 
Epub Date]|. 
28. Ryan TP. Modern Regression Methods. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2009. 
29. Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based 
measures: benefit or burden? Value Health 2012;15(3):504-13 doi: 
10.1016/j.jval.2011.12.003[published Online First: Epub Date]|. 
  
 
Figure and table legends 
Table 1. Time Trade-Off Utility Scores for 40 Health States Representing PASI Severity 
Table 2. Regression Models Estimating Utility Based on the Total PASI Score: Model Coefficients and 
Performance Statistics 
Table 3. Regression Models Estimating Utility Based on the Four PASI Location Scores: Model 
Coefficients and Performance Statistics 
Table 4. Recommended Models for Deriving Utilities from PASI Scores 
Figure 1. Example of a Health State 
Figure 2. Utility Curves Predicted by Regression Models Estimating Utility Based on the Total PASI Score 
Figure 3. Marginal Utility Curves Predicted by Regression Models Estimating Utility Based on the Four 
PASI Location Scores   
 
  
Ac
ce
pte
d M
an
us
cri
pt
 Figure 1. Example of a Health Statea  
You have been diagnosed with a chronic skin condition that produces thickened, red, scaly patches on 
your body. These patches are frequently itchy and dry. 
Head  
(including 
face, scalp, 
and neck) 
40% Surface Area Covering 40% of this body surface area 
4 Redness Fiery red 
3 Thickness Very raised and thickened 
3 Scaling Most of your patches are covered with thick, rough flakes 
Upper 
Limbs  
(including 
arms, 
shoulders, 
and hands) 
20% Surface Area Covering 20% of this body surface area 
1 Redness Light red 
1 Thickness Almost flat, but slightly raised and thickened 
1 Scaling Some of your patches are covered with fine flakes 
Trunk  
(including 
anything 
above the 
hips, such as 
the stomach, 
back, and 
chest) 
20% Surface Area Covering 20% of this body surface area 
1 Redness Light red 
1 Thickness Almost flat, but slightly raised and thickened 
1 Scaling Some of your patches are covered with fine flakes 
Lower 
Limbs 
(including all 
areas below 
the waist 
such as hips, 
buttocks, 
legs, and 
feet) 
40% Surface Area Covering 40% of this body surface area 
2 Redness Moderately red 
2 Thickness Moderately raised and thickened 
1 Scaling Some of your patches are covered with fine flakes 
a
 Health State 13 representing a PASI total score of 12. 
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Table 1. Time Trade-Off Utility Scores for 40 Health States Representing PASI Severity 
  Health State Symptom Severity: PASI Scores  
Valuation Study 
Results 
Severity 
Group 
HS 
# 
Total 
Score 
Head 
Upper 
Limbs 
Trunk 
Lower 
Limbs 
 
N 
Mean 
Utility
a
 
SD 
1 1 0.2 0 1 0 0  31 0.96 0.03 
1 2 2.6 2 3 2 3  31 0.90 0.16 
1 3 3.4 2 0 0 8  31 0.89 0.17 
1 4 4.1 10 3 3 4  29 0.89 0.11 
1 5 5.9 3 4 0 12  30 0.85 0.17 
1 6 6.2 4 4 10 5  31 0.90 0.08 
1 7 6.8 6 6 6 8  31 0.87 0.16 
1 8 7.8 4 14 6 7  31 0.85 0.20 
2 9 8.4 10 12 6 8  31 0.81 0.33 
2 10 8.8 0 3 6 16  31 0.92 0.08 
2 11 10.9 1 4 12 16  31 0.89 0.13 
2 12 11.4 10 10 12 12  31 0.83 0.20 
2 13 12 30 6 6 15  31 0.73 0.22 
2 14 13.2 12 14 12 14  30 0.82 0.22 
2 15 13.5 3 12 12 18  30 0.77 0.29 
2 16 14.2 6 16 24 8  30 0.78 0.30 
3 17 14.4 32 0 16 16  31 0.77 0.36 
3 18 14.6 12 10 14 18  31 0.76 0.29 
3 19 16.5 12 24 3 24  29 0.64 0.49 
3 20 17.6 24 16 12 21  31 0.71 0.31 
3 21 18 0 18 12 27  31 0.81 0.24 
3 22 18.4 0 7 14 32  31 0.80 0.29 
3 23 18.6 40 8 30 10  31 0.64 0.33 
3 24 19.3 15 14 14 27  30 0.74 0.30 
4 25 19.4 8 21 32 12  30 0.73 0.33 
4 26 20 20 20 20 20  31 0.70 0.35 
4 27 20.3 36 22 9 24  31 0.62 0.40 
4 28 21.6 21 24 21 21  30 0.71 0.28 
4 29 22.2 6 24 24 24  31 0.80 0.28 
4 30 23.4 18 24 24 24  30 0.69 0.35 
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   Health State Symptom Severity: PASI Scores  
Valuation Study 
Results 
Severity 
Group 
HS 
# 
Total 
Score 
Head 
Upper 
Limbs 
Trunk 
Lower 
Limbs 
 
N 
Mean 
Utility
a
 
SD 
4 31 25.2 28 28 28 21  31 0.57 0.43 
4 32 26.9 14 27 27 30  31 0.58 0.44 
5 33 29.1 28 36 45 14  31 0.58 0.44 
5 34 31.2 24 24 20 45  31 0.58 0.44 
5 35 34.3 35 28 28 42  31 0.57 0.48 
5 36 35.1 27 36 36 36  30 0.53 0.45 
5 37 36.4 40 48 36 30  29 0.51 0.44 
5 38 41.4 50 40 36 44  31 0.47 0.54 
5 39 44.3 20 33 55 48  31 0.61 0.44 
5 40 52.2 27 55 55 55  31 0.56 0.37 
a Time trade-off utility scores are on a scale anchored with 0 representing dead and 1 representing full health. 
HS = Health State; PASI = Psoriasis Area Severity Index  
 
 
Table 2. Regression Models Estimating Utility Based on the Total PASI Score: Model Coefficients and 
Performance Statistics 
 
OLS 
Linear 
Mean 
Value 
Linear 
Random 
Effects 
Linear 
Robust 
Linear 
OLS 
Spline
a
 
Robust 
Spline 
OLS 
Quadrati
c 
Robust 
Quadrati
c 
Intercept 0.91*** 0.91*** 0.91*** 0.93*** 0.96*** 0.95*** 0.98*** 0.96*** 
PASI 
-
0.0096**
* 
-
0.0096**
* 
-
0.0097**
* 
-
0.0055**
* 
-
0.013**
* 
-
0.0068**
* 
-
0.018*** 
-
0.0086**
* 
Add-on 
PASI > 
29 
-- -- -- -- 
0.011**
* 
0.0053**
* 
-- -- 
Quadrati
c Term 
-- -- -- -- -- -- 
0.00017*
* 
0.0001** 
Random 
Intercept 
Variance 
-- -- 0.063*** -- -- -- -- -- 
N 1225 40 1225 919 1225 919 1225 919 
R
2
 0.1103 0.7847 -- 0.0684 0.1197 0.0721 0.1181 0.0712 
Adjusted 
R
2
 
0.1095 0.7791 -- -- 0.1182 -- 0.1167 -- 
MAE-I
b
 0.2094 0.0457 0.1101 0.1946 0.2084 0.1935 0.2085 0.1938 
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 weighte
d MAE 
-- -- -- 0.1061 -- 0.1050 -- 0.1053 
MAE-
M
b
 
0.0457 0.0457 0.0382 0.1020 0.0381 0.1008 0.0410 0.1009 
Count 
>.05
c
 
15 15 12 26 13 26 13 26 
Count 
>.10
c
 
4 4 2 16 2 17 1 17 
Count 
>.05
c
 
weighte
d
d
 
-- -- -- 4 -- 3 -- 3 
Count 
>.10
c
 
weighte
d
d
 
-- -- -- 0 -- 0 -- 0 
a
 This is the alternate model recommended for deriving utilities from the PASI total score in situations when the four PASI 
location scores are not available. 
b
 MAE-I (mean absolute error at the individual level) is the mean of the absolute value of the difference between each 
observation (i.e., every utility score for every health state) and the predicted value based on the regression model.  For MAE-M 
(mean absolute error of utility means), the mean utility score of each health state was calculated first.  Then, the MAE-M was 
computed as the absolute value of the difference between this mean (i.e., the mean utility score for each health state) and the 
predicted value based on the regression model.   
c
 The number of mean residual errors greater than 0.05 or greater than 0.10 (i.e., the number of health states for which the 
difference between predicted and observed mean utility values exceed the specified threshold of 0.05 or 0.10) 
d
 The weighted observed mean utility scores used to calculate the mean residuals are obtained from the robust regression, which 
down-weighs outliers and high leverage points. 
*p < 0.05; **p < 0.01; *** p < 0.001 
 
 
 
Table 3. Regression Models Estimating Utility Based on the Four PASI Location Scores: Model 
Coefficients and Performance Statistics 
 
OLS 
Linear
a
 
Mean 
Value 
Linear 
Random 
Effects 
Linear 
Robust 
Linear 
OLS 
Spline 
Robust 
Spline 
OLS 
Quadrati
c 
Robust 
Quadrati
c 
Intercept 0.92*** 0.92*** 0.92*** 0.93*** 
0.95**
* 
0.95*** 0.96*** 0.96*** 
Head 
-
0.0047**
* 
-
0.0047**
* 
-
0.0047**
* 
-
0.0024**
* 
-
0.0053
* 
-
0.0037**
* 
-0.0052 -0.0041* 
Upper -0.0041* 
-
0.0041**
* 
-
0.0029** 
-
0.0027**
* 
-
0.0047
* 
-
0.0023** 
-0.0072* -0.0019 
Trunk -0.00014 -0.00011 -0.0015 -0.0003 
-
0.0008
-0.0010 -0.000029 -0.0006 
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OLS 
Linear
a
 
Mean 
Value 
Linear 
Random 
Effects 
Linear 
Robust 
Linear 
OLS 
Spline 
Robust 
Spline 
OLS 
Quadrati
c 
Robust 
Quadrati
c 
8 
Lower -0.0018 -0.0018* -0.0015* -0.0005 
-
0.0025 
-0.0012 -0.0042 -0.0031 
Add-on 
Head > 
20 
-- -- -- -- 0.0022 0.0033* -- -- 
Add-on 
Upper > 
40 
-- -- -- -- 0.0068 -0.0012 -- -- 
Add-on 
Trunk > 
36 
-- -- -- -- 0.0030 0.0034 -- -- 
Add-on 
Lower > 
21 
-- -- -- -- 
0.0008
3 
0.0008 -- -- 
Head-
squared 
-- -- -- -- -- -- 0.000014 0 
Upper- 
squared 
-- -- -- -- -- -- 0.000076 0 
Trunk- 
squared 
-- -- -- -- -- -- -0.000012 0 
Lower- 
squared 
-- -- -- -- -- -- 0.000049 0.0001 
Random 
Intercept 
Variance 
-- -- 0.063*** -- -- -- -- -- 
N 1225 40 
1225 
(245) 
1225 
(920) 
1225 
1225 
(921) 
1225 
1225 
(921) 
R
2
 0.1276 0.9073 -- 0.0789 0.1322 0.0824 0.1320 0.0821 
Adjusted 
R
2
 
0.1248 0.8967 -- -- 0.1265 -- 0.1263 -- 
MAE-I
b
 0.2070 0.0308 0.1085 0.1919 0.2062 0.1913 0.2063 0.1913 
weighted 
MAE 
-- -- -- 0.1032 -- 0.1033 -- 0.1026 
MAE-
M
b
 
0.0308 0.0308 0.0242 0.0992 0.0253 0.0975 0.0259 0.0980 
Count 
>.05
c
 
5 5 6 28 4 28 4 28 
Count 
>.10
c
 
1 1 1 21 0 15 0 16 
Count 
>.05
c
 
weighted
d
 
-- -- -- 1 -- 0 -- 0 
Count 
>.10
c
 
weighted
-- -- -- 0 -- 0 -- 0 
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Linear
a
 
Mean 
Value 
Linear 
Random 
Effects 
Linear 
Robust 
Linear 
OLS 
Spline 
Robust 
Spline 
OLS 
Quadrati
c 
Robust 
Quadrati
c 
d
 
a This is the primary model recommended for deriving utilities from the PASI.   
b MAE-I (mean absolute error at the individual level) is the mean of the absolute value of the difference between each 
observation (i.e., every utility score for every health state) and the predicted value based on the regression model.  For MAE-M 
(mean absolute error of utility means), the mean utility score of each health state was calculated first.  Then, the MAE-M was 
computed as the absolute value of the difference between this mean (i.e., the mean utility score for each health state) and the 
predicted value based on the regression model.   
c The number of mean residual errors greater than 0.05 or greater than 0.10 (i.e., the number of health states for which the 
difference between predicted and observed mean utility values exceed the specified threshold of 0.05 or 0.10) 
d The weighted observed mean utility scores used to calculate the mean residuals are obtained from the robust regression, which 
down-weighs outliers and high leverage points. 
*p < 0.05; **p < 0.01; *** p < 0.001 
 
 
Table 4. Recommended Models for Deriving Utilities from PASI Scores 
Name of Model Scoring Algorithm with Coefficients 
Primary Model:  
OLS Linear Model based on 
the Four PASI Location Scores  
Utility = 0.92 + (-0.0047 * PASI head) +  
(-0.0041 * PASI upper limbs) + (-0.00014 * PASI trunk) +  
(-0.0018 * PASI lower limbs) 
Alternate Model
a
:  
Spline Model based on the 
PASI Total Score 
Utility = 0.96 + (-0.013 * PASI total) +  
(0.011 * Max[0, PASI total ± 29])b 
a Recommended for use when the four PASI location scores are not available. 
b The term ³0D[>3$6,WRWDO± @´ is a derived variable which takes the value 0 when the PASI total score is less 
than or equal to 29, which is called the spline change SRLQWRU³NQRW.´  When the PASI total score is greater than 29, 
the value of this variable is PASI total score ± 29. 
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